Government, multinationals spar over insurance prices of new drugs

Published: 2010-09-17 07:00:00

Updated: 2010-09-17 07:00:00

The Korean government and some foreign drug manufacturers, including Pfizer Korea and MSD Korea and Abbott Korea, BMS Korea and GlaxoSmithKline, are walking a tightrope not to irritate each other, but their conflicting needs continue to put them at odds over the insurance prices of TNF-α inhibito...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK